← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Other antineoplastic agents
darinaparsin
L01XX82
Forms & Strengths
- Intravenous injection: 100 mg/vial, 300 mg/vial
- Lyophilized powder for injection
Adult Dosing
- 400 mg/m^2 on days 1, 3, and 5, every 2 weeks
- Recommended dose: 400 mg/m^2, administered IV over 1 hour
Pediatric Dosing
- No established dosage recommendations for pediatric patients
- Darinaparsin has not been studied in pediatric patients
Indications
- Treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)
- Acute myeloid leukemia (AML) in elderly patients
Mechanism of Action
- Inhibits glutathione S-transferase P1-1 (GSTP1-1) and triggers mitochondrial-mediated apoptosis
- Generates reactive oxygen species (ROS), leading to DNA damage and cell death
Contraindications
- Hypersensitivity to darinaparsin or its components
- Severe hepatic impairment
Adverse Reactions
- Nausea, fatigue, anemia, thrombocytopenia, neutropenia, and diarrhea
- Prolonged QT interval, and cardiac arrhythmias
Drug Interactions
- CYP3A4 inducers/inhibitors: potential for increased/decreased darinaparsin exposure
- QT-prolonging agents: increased risk of cardiac arrhythmias
Curated Content: Needs Vetting Before Put to Clinical Use